• Daiichi Sankyo's Hypertension Drug Hits Mark in Diabetic Nephropathy Trial

    Daiichi Sankyo partnered with Alameda, California-based Exelixis on the drug. Esaxerenone is a novel mineralocorticoid receptor (MR) blocker.

    Read More
  • 0 0